ECSP045319A - AMINOÁCIDOS CON AFINIDAD POR LA PROTEINA a2d - Google Patents
AMINOÁCIDOS CON AFINIDAD POR LA PROTEINA a2dInfo
- Publication number
- ECSP045319A ECSP045319A EC2004005319A ECSP045319A ECSP045319A EC SP045319 A ECSP045319 A EC SP045319A EC 2004005319 A EC2004005319 A EC 2004005319A EC SP045319 A ECSP045319 A EC SP045319A EC SP045319 A ECSP045319 A EC SP045319A
- Authority
- EC
- Ecuador
- Prior art keywords
- amino acids
- affinity
- protein
- psychiatric
- subunit
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
Abstract
Esta invención se refiere a ciertos b-aminoácidos que se unen a la subunidad alfa-2-delta (a2d) de un canal de calcio. Estos compuestos y sus sales farmacéuticamente aceptables son útiles en el tratamiento de una variedad de trastornos psiquiátricos del dolor y otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36841302P | 2002-03-28 | 2002-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045319A true ECSP045319A (es) | 2004-11-26 |
Family
ID=28675482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005319A ECSP045319A (es) | 2002-03-28 | 2004-09-28 | AMINOÁCIDOS CON AFINIDAD POR LA PROTEINA a2d |
Country Status (42)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129693A1 (de) * | 2001-06-22 | 2003-01-02 | Jan Loock | Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| BRPI0414798A (pt) | 2003-09-25 | 2006-11-21 | Warner Lambert Co | métodos para usar aminoácidos com afinidade para a proteìna alfa2delta |
| WO2005030700A2 (en) * | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Amino acids with affinity for the alpha2delta-protein |
| DE602005002253T2 (de) * | 2004-03-12 | 2008-05-29 | Warner-Lambert Company Llc | C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin |
| US20090247743A1 (en) * | 2004-07-09 | 2009-10-01 | Pfizer Inc | Preparation of beta-amino acids having affinity for the alpha-2-delta protein |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| WO2006100568A1 (en) * | 2005-03-24 | 2006-09-28 | Pharmacia & Upjohn Company Llc | Preparation of optically pure beta-amino acids having affinity for the alpha-2-delta protein |
| WO2007052134A1 (en) * | 2005-11-04 | 2007-05-10 | Pfizer Limited | (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use |
| US20090286875A1 (en) * | 2005-11-17 | 2009-11-19 | Pfizer, Inc. | Isocystene derivatives for the treatment of pain |
| RU2008135907A (ru) * | 2006-03-06 | 2010-04-20 | Пфайзер Продактс Инк. (Us) | Альфа-2-дельта лиганды для невосстановительного сна |
| AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| PL2710007T3 (pl) | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| US8962831B2 (en) | 2011-05-17 | 2015-02-24 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN103164756A (zh) * | 2011-12-12 | 2013-06-19 | 苏州艾隆科技有限公司 | 贵重药品的管理方法及其系统 |
| AU2013312296B2 (en) | 2012-09-10 | 2017-06-22 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR20160117614A (ko) | 2014-02-21 | 2016-10-10 | 프린시피아 바이오파마, 인코퍼레이티드 | Btk 억제제의 염 및 고체 형태 |
| EA036269B1 (ru) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Лечение пузырчатки |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| EP4045051A1 (en) | 2019-10-14 | 2022-08-24 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| PH12022551787A1 (en) | 2020-01-22 | 2024-02-12 | Principia Biopharma Inc | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2025078915A1 (en) * | 2023-10-12 | 2025-04-17 | Siemens Healthcare Diagnostics Inc. | Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1377736A (fr) * | 1962-12-21 | 1964-11-06 | Hoffmann La Roche | Procédé pour la préparation d'acides amino-carboxyliques |
| FR1377366A (fr) | 1963-08-19 | 1964-11-06 | Dispositif de protection de sécurité pour appareils électriques | |
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| AU7168091A (en) | 1989-12-22 | 1991-07-24 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
| US5614498A (en) | 1990-06-07 | 1997-03-25 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
| US5011066A (en) * | 1990-07-27 | 1991-04-30 | Motorola, Inc. | Enhanced collapse solder interconnection |
| US5239113A (en) | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
| EP0561758A3 (en) | 1992-03-18 | 1995-04-05 | Monsanto Co | Method of preparing optically active homo-beta-amino acids |
| US5578606A (en) * | 1992-10-30 | 1996-11-26 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
| AU684878B2 (en) | 1993-11-24 | 1998-01-08 | Merck & Co., Inc. | Compounds and the use thereof to promote the release of growth hormone(s) |
| AU700579B2 (en) | 1993-12-12 | 1999-01-07 | Agrogene Ltd | A novel method to protect plants from fungal infection |
| US5472830A (en) | 1994-04-18 | 1995-12-05 | Ocg Microelectronic Materials, Inc. | Non-corrosion photoresist stripping composition |
| CN1119321C (zh) | 1996-07-12 | 2003-08-27 | G·D·瑟尔公司 | 手性β－氨基酸的不对称合成 |
| ATE361909T1 (de) * | 1996-10-23 | 2007-06-15 | Warner Lambert Co | Substituierte gamma-aminobuttersäurederivate als arzneimittel |
| US6306909B1 (en) | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| GB2323594A (en) | 1997-03-25 | 1998-09-30 | Victor Martin | 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| US6011066A (en) | 1998-02-02 | 2000-01-04 | Veterans General Hospital-Taipei | Method for treating septic shock |
| EP1076563B1 (en) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| EP1013769A1 (en) | 1998-12-22 | 2000-06-28 | Dsm N.V. | Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity |
| FR2791982B1 (fr) | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| JP3904452B2 (ja) * | 1999-06-10 | 2007-04-11 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | モノ−およびジ置換３−プロピルガンマ−アミノ酪酸 |
| WO2001088101A2 (en) * | 2000-05-16 | 2001-11-22 | Warner-Lambert Company | CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT |
| CA2409253A1 (en) | 2000-05-17 | 2001-11-22 | Richard Francis William Jackson | Branched amino acids |
| AU1497802A (en) | 2000-09-14 | 2002-03-26 | Gruenenthal Chemie | Ss-thio-amino acids |
| DE10048715A1 (de) | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
| MXPA03008164A (es) * | 2001-03-13 | 2003-12-12 | Univ Kingston | Agentes anti-epileptogenos. |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| CN1228312C (zh) * | 2002-12-27 | 2005-11-23 | 中国科学院化学研究所 | 以酮为原料合成β—氨基酸的方法 |
-
2003
- 2003-03-06 NI NI200300043A patent/NI200300043A/es unknown
- 2003-03-17 CA CA2480872A patent/CA2480872C/en not_active Expired - Fee Related
- 2003-03-17 CN CNB038112698A patent/CN100462351C/zh not_active Expired - Fee Related
- 2003-03-17 PT PT03706831T patent/PT1492761E/pt unknown
- 2003-03-17 AU AU2003208538A patent/AU2003208538B2/en not_active Ceased
- 2003-03-17 PL PL373363A patent/PL209750B1/pl not_active IP Right Cessation
- 2003-03-17 SI SI200331654T patent/SI1492761T1/sl unknown
- 2003-03-17 BR BR0308814-6A patent/BR0308814A/pt active Search and Examination
- 2003-03-17 RS YUP-836/04A patent/RS83604A/sr unknown
- 2003-03-17 EP EP03706831A patent/EP1492761B1/en not_active Expired - Lifetime
- 2003-03-17 EA EA200401127A patent/EA008709B1/ru unknown
- 2003-03-17 DE DE60328469T patent/DE60328469D1/de not_active Expired - Lifetime
- 2003-03-17 KR KR1020057025293A patent/KR100694719B1/ko not_active Expired - Fee Related
- 2003-03-17 GE GEAP8423A patent/GEP20074123B/en unknown
- 2003-03-17 NZ NZ535364A patent/NZ535364A/en not_active IP Right Cessation
- 2003-03-17 KR KR1020047015361A patent/KR100630981B1/ko not_active Expired - Fee Related
- 2003-03-17 HR HRP20040891 patent/HRP20040891A2/hr not_active Application Discontinuation
- 2003-03-17 UA UA20040907854A patent/UA80116C2/uk unknown
- 2003-03-17 UA UAA200507455A patent/UA80018C2/uk unknown
- 2003-03-17 NZ NZ541320A patent/NZ541320A/en unknown
- 2003-03-17 HR HR20050764A patent/HRP20050764A2/hr not_active Application Discontinuation
- 2003-03-17 WO PCT/IB2003/000976 patent/WO2003082807A2/en not_active Ceased
- 2003-03-17 CN CNA2006100070283A patent/CN1817854A/zh active Pending
- 2003-03-17 IL IL16411003A patent/IL164110A0/xx unknown
- 2003-03-17 MX MXPA04009373A patent/MXPA04009373A/es active IP Right Grant
- 2003-03-17 GE GEAP20038907A patent/GEP20084298B/en unknown
- 2003-03-17 RS YUP-2005/0667A patent/RS20050667A/sr unknown
- 2003-03-17 JP JP2003580276A patent/JP3831379B2/ja not_active Expired - Fee Related
- 2003-03-17 OA OA1200400254A patent/OA12795A/en unknown
- 2003-03-17 DK DK03706831T patent/DK1492761T3/da active
- 2003-03-17 EA EA200501497A patent/EA200501497A1/ru unknown
- 2003-03-17 ES ES03706831T patent/ES2327910T3/es not_active Expired - Lifetime
- 2003-03-17 EP EP05108848A patent/EP1614675A3/en not_active Withdrawn
- 2003-03-17 AP APAP/P/2004/003144A patent/AP1791A/en active
- 2003-03-24 TW TW092106516A patent/TWI225864B/zh not_active IP Right Cessation
- 2003-03-25 PE PE2003000303A patent/PE20040349A1/es not_active Application Discontinuation
- 2003-03-25 MY MYPI20031051A patent/MY131424A/en unknown
- 2003-03-26 AR ARP030101060A patent/AR039154A1/es not_active Application Discontinuation
- 2003-03-27 US US10/401,060 patent/US7064147B2/en not_active Expired - Lifetime
- 2003-03-27 UY UY27738A patent/UY27738A1/es not_active Application Discontinuation
- 2003-03-28 GT GT200300072AK patent/GT200300072AA/es unknown
- 2003-03-28 GT GT200300072A patent/GT200300072A/es unknown
- 2003-03-28 PA PA20038570001A patent/PA8570001A1/es unknown
-
2004
- 2004-09-16 IS IS7451A patent/IS7451A/is unknown
- 2004-09-17 ZA ZA2004/07536A patent/ZA200407536B/en unknown
- 2004-09-24 MA MA27874A patent/MA27188A1/fr unknown
- 2004-09-27 CU CU20040212A patent/CU23331B7/es not_active IP Right Cessation
- 2004-09-27 TN TNP2004000186A patent/TNSN04186A1/fr unknown
- 2004-09-28 CR CR7501A patent/CR7501A/es unknown
- 2004-09-28 EC EC2004005319A patent/ECSP045319A/es unknown
- 2004-10-26 NO NO20044614A patent/NO20044614L/no not_active Application Discontinuation
-
2005
- 2005-07-01 US US11/173,073 patent/US20050272783A1/en not_active Abandoned
- 2005-07-20 AR ARP050102999A patent/AR050261A2/es unknown
- 2005-07-21 IL IL169820A patent/IL169820A0/en unknown
- 2005-07-21 IS IS7951A patent/IS7951A/is unknown
- 2005-07-28 JP JP2005218738A patent/JP3857714B2/ja not_active Expired - Fee Related
- 2005-08-23 NO NO20053918A patent/NO20053918L/no not_active Application Discontinuation
-
2006
- 2006-03-14 US US11/375,318 patent/US7517909B2/en not_active Expired - Fee Related
-
2009
- 2009-08-12 CY CY20091100858T patent/CY1109304T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045319A (es) | AMINOÁCIDOS CON AFINIDAD POR LA PROTEINA a2d | |
| CR8290A (es) | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2-d | |
| EP1487493A4 (en) | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOACTIVE PEPTIDES | |
| CY1116992T1 (el) | Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17 | |
| CY1124763T1 (el) | Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας | |
| CY1105082T1 (el) | Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας | |
| ECSP045258A (es) | Hidroxietilaminas sustituidas | |
| SV2003001103A (es) | Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester pc10894 | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| ECSP066575A (es) | Antagonistas del receptor b1 de bradiquinina | |
| CR10080A (es) | Preparacion de gamma-aminoacidos que tienen afinidad por la proteina alfa-2-delta | |
| BRPI0414798A (pt) | métodos para usar aminoácidos com afinidade para a proteìna alfa2delta | |
| BRPI0414819A (pt) | pró-fármacos de aminoácidos com afinidade para a proteìna alfa2delta | |
| DOP2003000616A (es) | Aminoacidos con afinidad por la proteina a2 | |
| UY29033A1 (es) | Aminoácidos con afinidad por la proteína a2o (alfa 2 delta) | |
| DOP2004001000A (es) | Aminoacidos con afinidad por la proteina | |
| ES2117475T5 (es) | Utilizacion de acidos monocarboxilicos para el tratamiento de las materias queratinicas. | |
| GT200400189A (es) | Aminoacidos con afinidad por la proteina a2d. | |
| ATE402703T1 (de) | Tablette enthaltend efletirizin und pseudoephedrin | |
| HN2003000108A (es) | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2o´ | |
| AR056952A1 (es) | PREPARACIoN DE BETA-AMINOÁCIDOS oPTICAMENTE PUROS CON AFINIDAD POR LA PROTEíNA ALFA-2-DELTA | |
| SE0101257D0 (sv) | Treatment of whiplash associated disorder |